Clinuvel Pharmaceuticals (ASX:CUV) reported Thursday that its earnings per diluted share in the fiscal first half rose to AU$0.28 from AU$0.212 a year earlier.
Analysts polled by Visible Alpha were expecting an EPS of AU$0.20.
Revenue for the six months ended Dec. 31, 2024, was AU$35.6 million, up from AU$32.3 million in the same period a year earlier. Analysts surveyed by Visible Alpha expected AU$35.6 million.
The company's shares rose past 8% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.